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T cell responseThe association of vitamin D deﬁciency with higher prevalence, relapse rate and progression of multiple
sclerosis (MS) has stimulated great interest in using vitamin D supplementation as a preventative measure and
even a therapy for established MS. However, there is a considerable lack of evidence when it comes to an age/
developmental stage-dependent efﬁcacy of vitamin D action and a time-window for the most effective
prophylactic treatment remains unclear.
We studied the effect of vitamin D supplementation in myelin oligodendrocyte glycoprotein (MOG)-induced
experimental autoimmune encephalomyelitis (EAE), an animal model of MS, at three different developmental
stages in rats. Supplementation treatment was initiated: i) prior to gestation and maintained throughout pre-
and early postnatal development (gestation and lactation); ii) after weaning, throughout juvenile/adolescence
period and iii) in adult age. We observed a marked attenuation of EAE in juvenile/adolescent rats reﬂected in a
less severe CNS inﬂammation and demyelination, accompanied by a lower amount of IFN-γ producing MOG-
speciﬁc T cells. Moreover, the cytokine expression pattern in these rats reﬂected a more anti-inﬂammatory
phenotype of their peripheral immune response. However, the same supplementation regimen failed to improve
the disease outcome both in adult rats and in rats treated during pre- and early post-natal development.
Our data demonstrate a developmental stage-dependent efﬁciency of vitaminD to ameliorate neuroinﬂammation,
suggesting that childhood and adolescence should be the target for the most effective preventive treatment.
© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-SA license.Background
Multiple sclerosis (MS) is a chronic inﬂammatory disease of the
central nervous system (CNS) associated with demyelination, axonal
loss and brain atrophy (Hemmer et al., 2002). MS likely develops in
genetically predisposed individuals exposed to certain environmental
factors (Fugger et al., 2009; Sawcer et al., 2011). A lack of vitamin D is
one of the most frequently reported environmental factors in etiology
ofMS (Ascherio et al., 2010; Pierrot-Deseilligny and Souberbielle, 2010).
Epidemiological studies indicate thatMSprevalence varieswith geo-
graphical latitude (Pugliatti et al., 2002; Simpson et al., 2011) and it is
increased in regions further south or north beyond the 40th parallels
(Webb et al., 1988). Furthermore, the correlation betweenMS incidenceartment of Clinical Neuroscience,
7176 Stockholm, Sweden.
.Z. Adzemovic).
istry and Biophysics, Vascular
. Open access under CC BY-NC-SA licenand UVB radiation is 20 times higher than calculatedwith latitude alone
(Sloka et al., 2011). UVB is required for producing active vitaminD in the
skin (Holick, 1995) and its production progressively decreases with
geographical latitude (Chapuy et al., 1997), indicating an association
of vitamin D and MS pathogenesis. Interestingly, MS prevalence is up
to 50% lower in children born during autumn compared to those born
during spring in Scotland (Willer et al., 2005). This could be related to
sunlight/UVBexposure duringpregnancy, as the serum levels of vitamin
D are the lowest in spring and the highest in autumn. Notably, a recent
study reported that MS risk was lower among women whose mothers
had increased vitamin D intake during pregnancy (Mirzaei et al., 2011).
Low levels of circulating vitamin D are reported to predict subse-
quently increased risk for developing MS (Munger et al., 2006) and
MS patients themselves are deﬁcient in vitamin D (Nieves et al., 1994).
These observations stimulated a great interest in using vitamin D sup-
plementation not only as a preventative measure but also as a therapy
for MS and other inﬂammatory diseases. However, the protective effect
of vitamin D supplementation in MS has not yet been unequivocally
established (Papeix and Lubetzki, 2013). In development of a successful
treatment strategy it should be considered that many lifestyle and envi-
ronmental factors associated with MS seem to act particularly during
childhood and adolescence, such as migration (Gale and Martyn,se.
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Fig. 1.Diet regimen and experimental outline. For juvenile/adolescent and adult treatments,
3-week-old newly-weaned and 3-month-old, respectively, female rats were assigned into
three groups and subjected to either: i) vitaminD deprived diet; ii) diet containing a regular
amount of vitamin D or iii) a vitamin D supplemented diet. EAE was induced four to ﬁve
weeks after initiation of the diet regimen in both juvenile/adolescent and adult rats and
lasted for the next 31 days p.i, when the animals were sacriﬁced for histopathological and
IHC analyses. For pre- and early post-natal treatments, 3-week-old newly weaned female
rats were subjected to one of the three diets 5 to 6 weeks prior to breeding, throughout
gestation and lactation until weaning of the pups. The dams were sacriﬁced after weaning
and their offspring was subsequently subjected to diet containing a regular amount of
vitamin D until the end of the experiment. In these pre- and early post-natally treated
offspring EAE was induced 6 to 7 weeks after their weaning and lasted 31 days p.i.
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index (Hedstrom et al., 2012) and even infectious mononucleosis
(Handel et al., 2010). It has been reported that vitamin D supplementa-
tion during childhood decreases the risk of developing certain autoim-
mune diseases such as type I diabetes (Forouhi et al., 2008).
Based on these observationswe suspected an age-dependent efﬁcacy
of vitamin D to prevent or ameliorate neuroinﬂammation andwe aimed
to elucidate the most appropriate timing for the treatment. To that end
we analyzed the effects of vitamin D supplementation on myelin oligo-
dendrocyte glycoprotein (MOG)-induced experimental autoimmune
encephalomyelitis (EAE) in Dark Agouti (DA) rats during different
developmental stages. MOG-EAE in DA rats displays striking similarities
to MS: a relapsing–remitting disease course, MHC-dependence, histo-
pathological features and pathogenic T- and B-cell responses (Gold
et al., 2000; Storch et al., 1998; Weissert et al., 1998). It has been exten-
sively shown that vitamin D can prevent and block progression of EAE in
mice (Joshi et al., 2011; Lemire and Archer, 1991; Meehan and DeLuca,
2002; Nashold et al., 2009; Spach et al., 2006). Importantly, the vitamin
D receptor (VDR) is not only necessary for the suppressive effect of
vitaminD on EAE (Meehan andDeLuca, 2002), but EAE does not develop
in animals deﬁcient in vitamin D and VDR (Wang et al., 2012).
Our data demonstrate that only during juvenile/adolescence period,
but not during other developmental stages, a ﬁve-fold elevated intake of
vitamin D was sufﬁcient to signiﬁcantly ameliorate EAE. The protective
effect was reﬂected in decreased brain inﬂammation and better myelin
and axon preservation accompanied by an anti-inﬂammatory cytokine
expression pattern.
Materials and methods
Ethical statement
All experiments in this studywere performed in accordancewith the
guidelines from the Swedish National Board for Laboratory Animals and
the European Community Council Directive (86/609/EEC) under ethical
permits approved by the North Stockholm Animal Ethics Committee
(StockholmsNorra djurförsöksetiska nämnd). Ratswere tested according
to a health-monitoring program at the National Veterinary Institute
(Statens Veterinärmedicinska Anstalt, SVA) in Uppsala, Sweden.
Animals, vitamin D supplementation and EAE induction
Inbred Dark Agouti (DA) rats were housed in the animal facility at
Karolinska Hospital (Stockholm, Sweden) in a speciﬁc pathogen-free
and climate-controlled environment in polystyrene cages containing
aspen wood shavings with free access to rodent chow and water with
regulated 12-hour light/dark cycles free of UV radiation.
Experimental setting and diet regime based on different contents of
vitamin D3 (cholecalciferol; referred to as vitamin D) is present in detail
in Fig. 1. Age-matched inbred female rats were subjected to either:
i) supplemented diet containing ﬁve-fold increased amount of vitamin
D than the regular rat diet (10 International Units/g (IU/g)); ii) regular
rat diet containing 2 IU/g of vitamin D; or iii) vitamin D deprived diet
(0 IU/g). The supplemented and deprived diet formulations were
obtained from TestDiet Limited (London, UK).
All rats used in this study were weaned at an age of three weeks.
Newly weaned pups and three month old, young adult rats were
assigned into groups and supplied with one of the three different diets
four to ﬁve weeks prior to immunization and continuously until the
end of the EAE experiment. Each experimental group contained at
least six and at most 16 animals (repeated twice, for details please see
Supplementary Table 1). In order to analyze the effect of vitamin D
during pre- and early postnatal development, DA females were fed
with either deprived, regular or supplemented vitamin D diet starting
ﬁve to six weeks prior to gestation then continuously during gestation,
throughout lactation until weaning of the pups. From weaning untilthe end of the experiment all offspring received regular diet. Six to 11
animals were assigned into each experimental group (repeated twice;
Supplementary Table 1). Supplemented, deprived and control litter-
mate offspring were age-matched and immunized to induce EAE at
the young adult age of 10–12 weeks.
Myelin oligodendrocyte protein (MOG, amino acids 1–125 from the N
terminus) used for EAE inductionwas expressed inEscherichia coli andpu-
riﬁed to homogeneity by chelate chromatography (Amor et al., 1994). The
puriﬁed protein, dissolved in 6 M urea, was dialyzed against phosphate
buffered saline (PBS) to obtain a physiological preparation that was
stored at−70 °C. To induce EAE, rats were anesthetized with isoﬂurane
(2-chloro-2-(diﬂuoromethoxy)-1,1,1-triﬂuoro-ethane, Forene, Abbott
Laboratories, Chicago, IL, USA) and injected subcutaneously in the tail
base with a 200 μL inoculum containing 15 μg MOG in PBS, emulsiﬁed
1:1 with incomplete Freund's adjuvant (Sigma-Aldrich, St. Louis, MO,
USA). The serum levels of 25-hydroxy vitamin D (25(OH)D) were esti-
mated on day 7 post-immunization (p.i) using a chemiluminescent im-
munoassay from Diasorin (Diasorin AB, Sundbyberg, Sweden) and a
LIAISON® instrument provided by Diasorin ABwith equimolarmeasure-
ment of both 25-OHvitaminD2 andD3. ELISA kits for 25(OH)Dwere pur-
chased from Euroimmun AG (Luebeck, Germany) and used according to
themanufacturer's instructions to conﬁrm themeasurements of 25(OH)
D serum levels. This ELISA detects 25-OH vitamin D2 and D3 speciﬁcally
and cross-reactions with other metabolites such as vitamin D2, D3 and
cholesterol were less than 0.02% and 0.04%, respectively.
EAE phenotyping
Rats were monitored daily for clinical signs of EAE from day 7 p.i
until sacriﬁced on day 30 or 31 p.i. The scoring of clinical symptoms
was performed as follows: 0 = no detectable clinical signs; 1 = tail
weakness or paralysis; 2 = hind limb hemiparesis or paraparesis;
3 = hind limb paralysis and 4 = tetraplegy ormoribund. The following
disease parameters were assessed for each animal: onset of EAE (the
ﬁrst day with clinical disease manifestation), maximum EAE score
(the highest clinical score observed during EAE), cumulative EAE score
(the sum of daily clinical scores) and duration of EAE (the number of
days with manifested disease).
Quantitative real-time PCR
Five to seven animals from each diet regimen (experiment repeated
twice) were sacriﬁced on day 7 p.i using CO2 and draining inguinal
lymph nodes were collected in DMEM (Gibco-BRL, Grand Island, NY,
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screen to obtain single cell suspension (SCS). Total RNA was extracted
from the SCS using the RNeasy kit (Qiagen, Hilden, Germany) and the
QIAcube (Qiagen) including on column DNA-digestion for fully auto-
mated sample preparation. RNA concentration and purity was deter-
mined through measurement of A260/A280 ratio with a NanoDrop
ND-1000 Spectrophotometer (NanoDrop Technologies, Wilmington,
DE, USA). Conﬁrmation of RNA quality was assessed using the Agilent
2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). cDNA
was prepared using the iScript kit (Bio-Rad, Hercules, CA, USA). Quanti-
tative real-time PCR (qPCR) was performed using a CFX384 touch real
time PCR detection system (Bio-Rad) with a two-step PCR protocol
(95 °C for 10 min followed by 40 cycles at 95 °C for 10 s and 60 °C for
30 s and 45 cycles of melt curve analysis), using SYBR Green (Bio-Rad)
as the ﬂuorophore. Relative expression levels, corrected for ampliﬁca-
tion efﬁciency, were analyzed using the CFX manager software (Bio-
Rad). Relative expression was calculated as the ratio between the target
and Gapdh. Serial 10-fold dilutions from a pool of undiluted samples
within the study were used as standard. The following primers were
used for SYBR Green: Gapdh_fw TCA ACT ACA TGG TCT ACA TGT TCC
AG, Gapdh_rev TCC CAT TCT CAG CCT TGA CTG; Il2_fw CGA TAA TT A
CAA GAA TCT GAA ACT CC, Il2_rev TTT CCA GCG TCT TCC AAG TG;
Il4_fw CTT ACG GCA ACA AGG AAC ACC, Il4_rev CTT TCA GTG TTG TGA
GCG TGG; Icam_fw GCA GAT GGT GTC CCG CTG CC, Icam_rev CCA CGA
TCA CGA AGC CCG CA; Ifnγ_fw AAA GAC AAC CAG GCC ATC AGC,
Ifnγ_rev TGG CGA TGC TCA TGA ATG C; Cd80_fw TGA CTT CCC TAC
CCC CAA CAT, Cd80_rev CGG AAG CAA AGC AGG TAA TCC; Foxp3_fw
TGC CAC CTG GAA TCA ATG T, Foxp3_ rev CGT GGG AAG GTG CAG AGT
AGA; il17a_fw CTC AGA CTA CCT CAA CCG TTC C, il17a_ rev GTG CCT
CCC AGA TCA CAG AAG; Rorc_fw TTT GAA GGC AAA TAC GGT GGT G,
Rorc_rev TGT CGA TGA GTC TTG CAG AGA TG.
FACS analysis
Six animals fromeach experimental group/diet regimen (experiment
repeated twice) were sacriﬁced 7 days p.i. Obtained SCS from the
draining inguinal lymph nodes was subsequently washed and cells
were resuspended in PBS. A triple staining procedure was performed
with the following targets: CD3-FITC, CD4-APC and CD45RA-PE
(incubation with directly labeled primary antibodies purchased from
BD Biosciences, San Jose, CA, USA, 1:100, for 30 min at 4 °C). Target
staining and control staining were visualized using a FACS Calibur
(BD, Franklin Lakes, NJ, USA) with CellQuest software (version 3.2.1f1,
BD) and analyzed using Kaluza software (Beckman Coulter, CA, USA).
Elispot analysis
Four spleenswere harvested fromeach vitaminD supplemented and
deprived group (repeated twice) on day 10 p.i and placed in DMEM
before beingmechanically separated and passed through amesh screen.
Splenocytes of the rats treated with vitamin D supplemented or
deprived diets were used for IFN-γ Elispot analysis (R&D systems) in
96 well plates. Concanavalin A (ConA, 0.125 ng/μL), myelin oligoden-
drocyte protein (MOG, 0.5 ng/μL) and myelin basic protein (MBP,
0.5 ng/μL) were used to stimulate 50,000 splenocytes/well. After 48 h
incubation, IFN-γ production was visualized by antibody staining
according to the manufacturer's protocol and the colony forming units
(CFUs) were visualized using an AID Elispot reader (AID, Germany).
Histopathological and immunohistochemical analyses
On day 31 p.i, seven to 12 animals from each diet regimen were
euthanized using CO2 and perfused via the left heart ventricle with PBS
followed by 4% paraformaldehyde. Paraformaldehyde-ﬁxed 3–5 mm
thick parafﬁn embedded sections of the brain and spinal cord were
dewaxed in xylol, rehydrated and then stained with hematoxylin &eosin (HE) and Luxol Fast Blue (Kluever, KL) to assess tissue inﬂamma-
tion and demyelination, respectively. The inﬂammatory index (I.I.) and
demyelination score (DM) were determined from the number and size
of demyelinated lesions in each animal on an average of ﬁfteen complete
spinal cord cross-sections as previously described (Storch et al., 1998).
For immunohistochemistry (IHC), parafﬁn sections of the spinal
cord were treated as previously described (Bradl et al., 2005). After
performing antigen retrieval as previously described (Adzemovic
et al., 2012), sections were incubated with 10% fetal calf serum (FCS)
in 0.1 mol/L PBS prior to incubation with primary antibody at 4 °C,
overnight. After washing in PBS, sections were incubated with
biotinylated secondary antibody in 10% FCS in PBS for 1 h at room
temperature (anti-mouse or -rabbit, Amersham Pharmacia Biotech,
1:200). Finally, avidin peroxidase (1:100, Sigma, Vienna, Austria) was
applied for 1 h at room temperature and subsequently visualized with
3,3′diaminobenzidine-tetrahydrochloride (DAB, Sigma, Austria). Evalu-
ationwas performed on at leastﬁfteenwhole spinal cord cross-sections.
Imaging was performed using a Leica Polyvar 2 microscope. In adjacent
serial sections IHC was performed by using antibodies against the
following targets: lysosomes of rat activatedmacrophages andmicroglia
cells (ED1,mouse anti-ratmonoclonal antibody, AbD Serotec, Germany;
1:1000), rat T lymphocytes (W3/13, mouse anti-rat, Abcam, UK, 1:100)
and anti-amyloid precursor protein (APP, mouse anti-rat, Millipore
Chemikon, 1:500), complement components (mouse monoclonal anti-
C1q antibody (Abcam UK, 1:100), mouse monoclonal complement C3
antibody (Novus Biologicals, UK, 1:400), rabbit polyclonal anti-C5b-9
antibody (Bioss, USA, 1:500)) and immunoglobulins (goat anti-rat IgG
(biotinylated, GE Healthcare, 1:200) and goat anti-rat IgM antibody
(biotinylated, Novus Biologicals, UK, 1:1000)). Control sections were
incubated in the absence of primary antibody with non-immune FCS.
Statistical analysis
Statistical analyses of clinical EAE parameters, histopathology and
qPCR data were performed using non-parametric Kruskal–Wallis test
followed by Dunn's multiple comparison test for all pairs of analyzed
groups. Statistical analyses of FACS data were performed with ANOVA
followed by Bonferroni's multiple comparison for all pairs of analyzed
groups. Since the regular diet (2 IU/g vitamin D) was primarily used
as a control, statistical signiﬁcances indicated in the ﬁgures refer to
comparison between vitamin D deprived and vitamin D supplemented
groups. Elispot data comparisons between the two diet regimens, for
each stimulation, were analyzed with t-test.
Results
A vitamin D supplementation regimen is sufﬁcient to ameliorate EAE only in
juvenile/adolescent rats, but not in the other developmental stages
We analyzed the effect of the same vitamin D supplementation
regimen on EAE at different developmental stages (Fig. 1). The supple-
mentation was associated with a signiﬁcantly milder EAE course in
juvenile/adolescent rats, in contrast to the groups receiving regular or
vitamin D deprived diet (Fig. 2A). In addition, both maximal and
cumulative EAE scores and EAE duration were signiﬁcantly reduced in
juvenile/adolescent rats fed with the supplemented diet (Fig. 2B). The
EAE incidence was 100% in the rats subjected to vitamin D deprived or
regular diets and 89% in the rats receiving the supplementation. In
contrast to juveniles/adolescents, this supplementation was insufﬁcient
to affect the severity of the clinical disease either in adult (Figs. 2C and
D) or in the pre- and early post-natally treated rats (Figs. 2E and F).
Notably, the ﬁve-fold enhanced vitamin D supplemented diet increased
serum levels of 25(OH)D comparably in juvenile/adolescent and adult
rats in contrast to rats receiving the vitamin D deprived diet: 385.4 ±
83.5 nmol/L versus (vs.) 11.3 ± 2.6 nmol/L (MV ± SD) in juvenile/
adolescent and 389.0 ± 32.5 nmol/L vs. 93.9 ± 12.8 nmol/L (MV ±
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Fig. 2. The vitaminD supplementation regimen ameliorates clinical symptoms in juvenile/adolescent, but not in adult rats or in rats treated during pre- and early post-natal development.
(A) Juvenile/adolescent rats subjected to the vitaminD supplemented diet developed less severe EAE than the groups receiving either vitaminD deprived or the regular diet. Such effect of
the ﬁve-fold vitamin D enriched diet was not observed either in (C) adult or in (E) pre- and early post-natally treated rats. Graphical presentations of the maximal and cumulative
EAE scores, duration and onset of EAE in juvenile/adolescent (B), adult and (D) pre- and early post-natally treated rats (F); data obtained from the experiments shown in A, C and E,
respectively. Graphs represent data from two pooled independent experiments with similar outcome (details are given in Supplementary Table 1). All disease parameters presented
were signiﬁcantly downregulated due to the supplementation regimen in juveniles/adolescents, but not in adult or in rats treated during pre- and early post-natal development. Error
bars represent SEM. Statisticswere calculated using Kruskal–Wallis testwith Dunn's correction formultiple testing (p b 0.05 = *, p b 0.01 = **, p b 0.001 = ***). Statistical signiﬁcances
refer to comparison between vitamin D deprived and vitamin D supplemented groups.
42 M.Z. Adzemovic et al. / Experimental Neurology 249 (2013) 39–48SD) in adult rats. Serum levels of 25(OH)D of 193.0 ± 18.5 nmol/L
(MV ± SD) were measured in juveniles/adolescents fed with the diet
containing a regular amount of vitamin D.
According to histopathological and IHC analyses, juveniles/
adolescents, but not adult rats subjected to the supplemented diet
displayed signiﬁcantly less severe neuroinﬂammation and myelin loss
than the age-matched groups receiving either vitaminDdeprived or reg-
ular diets (Fig. 3). Milder clinical disease course in juvenile/adolescent
rats subjected to the supplemented diet was mirrored in less numerous,
lower size demyelinated lesions, overall lower recruitment of ED1+
macrophages and less abundant axonal damage. The amount of
inﬁltrating W3/13+ lymphocytes did not, however, signiﬁcantly differFig. 3. The vitamin D supplementation regimen ameliorates CNS inﬂammation and demyelinat
cord cross-sections of rats subjected to different levels of vitamin D in their diet. Histopathologi
31 p.i of each experimental group/diet regime, for both juvenile/adolescent and adult rats. T
(HE; AII–CII and JII–LII) and also against ED1 (AIII–CIII and JIII–LIII), W3/13 (AIV–CIV and JIV–
inﬂammatory index (I.I.; E, N) in juvenile/adolescent and adult rats, respectively and also recr
Q). Error bars represent SEM. Statistics were calculated using Kruskal–Wallis test with Dun
refer to comparison between vitamin D deprived and vitamin D supplemented groups.between the diet regimens in both age groups. The pathology of
juvenile/adolescent spinal cord affected with demyelinated lesions
was further analyzed for antibody extravasation and complement
activation. Staining with isotype-speciﬁc antibodies against IgG and
IgM revealed the highest immunoreactivity in the groups that were
receiving either regular or vitamin D deprived diet (Fig. 4). Similar to
C3 (Fig. 4), deposition of C1q complement component was generally
reduced upon vitamin D supplementation (data not shown), corre-
sponding to overall lower extent of demyelination observed in this
group. Notably, in contrast to rats that received vitamin D deprived
diet or regular amounts of vitamin D, the presence of C5b-9 was almost
completely abolished in the vitamin D supplemented group (Fig. 4).ion in juvenile/adolescent, but not in adult rats. Group representative images of the spinal
cal and IHC analyses performed on 7–12 parafﬁn embedded spinal cords harvested on day
issue cross-sections were stained with Kluever (KL; AI–CI and JI–LI), Hämalaun & eosin
LIV) and APP (AV–CV and JV–LV) in order to reveal demyelination score (DM; D, M) and
uitment of ED1+ macrophages (F O), W3/13+ T cells (G, P) and axonal damage (APP; H,
n's correction for multiple testing (p b 0.05 = *, p b 0.01 = **). Statistical signiﬁcances
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Fig. 4. Antibody extravasation and complement activation in the spinal cord of juvenile/adolescent rats affected by inﬂammation/demyelination evidenced the humoral immunity.
Group-representative neuropathology of spinal cord in juvenile/adolescent rats with EAE fed either with vitamin D supplemented (AI–DI), regular (AII–DII) or deprived (AIII–DIII) diet
(IHC was performed on the same tissue as histopathology and IHC presented in Fig. 3). Analysis of the Ig isotypes IgG (AI–AIII) and IgM (BI–BIII) revealed the lowest immunoglobulin
reactivity in the vitamin D supplemented group (AI, BI respectively) compared to the other two diet regimens (AII, BII and AIII, BIII, respectively; magniﬁcation ×100). Staining for
C3 (CI–CIII; magniﬁcation ×100) revealed massive depositions upon regular diet (CII) and vitamin D deprived diet (CIII) matching the demyelinated areas. C3 deposition in the treated
animal (CI) is much reduced and mainly restricted to the perivascular area (arrows). C5b-9 was detected in the lesions of rats that received regular diet (DII) and vitamin D deprived
diet (DIII). Virtually no C5b-9 depositions in the lesions of the vitamin D supplemented rat (DI). Staining revealed also the presence of granulocytes in the lesions of rats fed with vitamin
D deprived (DIII) and the regular diet (DII), whereas the inﬁltrate in the vitamin D supplemented animals is mainly composed of mononuclear cells (DI).
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predominantly in juvenile/adolescent rats compared to the other
developmental stages
In order to investigate whether the ﬁve-fold increased regular
vitamin D intake is associated with differential immune activation, we
analyzed mRNA expression levels of cytokines in the inguinal lymph
nodes harvested 7 days p.i. At this stage susceptible DA rats mount a
strong immune response against MOG, which subsequently leads to
inﬁltration of cells into CNS and signs of clinical disease (Thessen
Hedreul et al., 2009). Expression level of Il4, a key effector cytokine of
the anti-inﬂammatory Th2-like immune response, was signiﬁcantly
higher in juvenile/adolescent rats subjected to the supplemented diet
in contrast to those fed with vitamin D deprived food (Fig. 5A). In addi-
tion, we observed decreased Ifnγ and Il2 mRNA expression levels in
juvenile/adolescent rats subjected to the supplemented diet, both of
these cytokines being associated with a pro-inﬂammatory Th1-like
immune response. Rorc, which encodes RORgt, a transcription factor
promoting T cell differentiation into Th17 cells was decreased with
vitamin D supplementation regimen. The differences in Il17 expression
were, however, not signiﬁcantly different between experimental groups
of all three ages/developmental stages (data not shown). Further,
expression levels of the co-stimulatory molecule Cd80 and the adhesion
molecule Icam were signiﬁcantly decreased in juvenile/adolescent rats
fed with the supplemented diet (Fig. 5A).
None of these changes were observed in adult rats (Fig. 5B) except
for differential Foxp3 expression. Interestingly, upregulation of the regu-
latory T cell transcription factor observed in both juvenile/adolescent
and adult rats directly exposed to vitamin D supplementation in the
diet was not detected in the indirectly supplemented offspring. Notably,
this offspring that received supplementation during pre- and earlypostnatal development via mothers expressed a tendency to
downregulate Ifnγ (Fig. 5C).
Inﬂuence of the ﬁve-fold enhanced vitamin D intake on the main immune
cell populations prior to clinical disease onset
To investigate the impact of the same vitamin D supplementation
regimen at different developmental stages on the main immune cell
types during the initial phase of EAE we performed FACS analysis on
ex vivo inguinal lymph node cells harvested on day 7 p.i. The CD4+
cell subset was generally more abundant in young than in adult exper-
imental animals subjected to the supplemented diet, whichwas accom-
panied by signiﬁcantly lower amounts of CD45RA+ B cells. We did not
observe such a trend in CD45RA+/CD4+ cell ratio in juvenile/adolescent
and in the pre- and early post-natally treated rats subjected to the
vitamin D deprived diet (Figs. 6A, C). In contrast to rats treated in the
earlier developmental stages, the same supplementation regimen
made no signiﬁcant impact on the main immune cell populations in
adult age (Fig. 6B). We observed no age or diet regimen-dependent
difference in amounts of CD8+ T within all experimental groups.
Suppressed T cell responses towards MOG predominantly in juvenile/
adolescent rats receiving vitamin D supplementation
Todetect potential vitaminD level-dependent differences in response
to the speciﬁc CNS antigen MOG at different developmental stages, we
performed IFN-γ Elispot analyses on day 10 p.i with ex vivo splenocytes.
The speciﬁc T cell response towardsMOG antigenwas reduced by 80% in
the juvenile/adolescent rats receiving the supplemented diet compared
to those fed with the vitamin D deprived diet (Fig. 6D). A signiﬁcant
modulation of the MOG-speciﬁc autoimmune response was also
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Elispot differences were analyzed using t-test (p b 0.05 = *, p b 0.01 = **). Statistical
signiﬁcances refer to comparison between vitamin D deprived and vitamin D
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less, such vitamin D supplementation-related effect was not observed
in adult rats. Importantly, the responses to ConA (positive control) and
myelin basic protein (MBP, non-speciﬁc CNS antigen) were similar
between the groups.
Discussion
Numerous studies provide evidence for strong associations of
vitamin D with development of MS and EAE, indicating prospects for
treatment of thedisease based on vitaminD supplementation.However,
a conclusive demonstration of the efﬁcacy of vitamin D in MS is still
missing (Papeix and Lubetzki, 2013), especially in terms of the most
sensitive age/developmental stage. We aimed to address this question
by investigating the effect of the same vitamin D supplementation
regimen during different developmental stages in a setting of rat
neuroinﬂammation. Since confounding factors such as body mass
index, season and lifestyle can additionally affect susceptibility to MS
(Handel et al., 2011), our study was performed in age-matched inbred
female rats housed under equal environmental conditions, whichruled out the effect of age, gender and genetic background. While it
signiﬁcantly ameliorated EAE in juvenile/adolescent rats, the same
supplementation regimen was insufﬁcient to affect clinical disease in
both adult rats and rats treated during pre- and early post-natal
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adolescence period has the highest sensitivity to vitamin D. Our data
conformwithmany epidemiological studies that associate sun exposure
during childhood and adolescence with the lower risk for MS (Dalmay
et al., 2010; Islam et al., 2007; Kampman et al., 2007; McDowell et al.,
2010; van der Mei et al., 2003). Moreover, women who received higher
levels of vitamin D from supplements during adolescence have a
reduced risk for developing MS (Munger et al., 2011). Finally, a retro-
spective study in pediatric MS reported that every 10 ng/mL increase
in serum vitamin D3 level was associated with a 34% decrease in the
rate of subsequent disease relapses (Mowry et al., 2010).
There is a considerable variation in the supplementation strategies
and doses proven to successfully ameliorate EAE in rodents (Joshi
et al., 2011; Lemire and Archer, 1991; Nashold et al., 2009; Nataf et al.,
1996; Spach et al., 2006). We demonstrated that a ﬁve-fold higher
than regular amount of vitamin D, when administered in a continuous,
physiological way via diet, is sufﬁcient to ameliorate neuro-
immunological disease in juvenile/adolescent rats, but not in the other
developmental stages. Nevertheless, this supplementation signiﬁcantly
elevated 25(OH)D serum levels in both juvenile/adolescent and adult
rats.
Vitamin D exhibits a variety of immunomodulatory functions (Mora
et al., 2008). Human in vitro studies demonstrated an anti-proliferative
effect of vitamin D on T and B cells (Chen et al., 2007; Iho et al., 1986;
Lemire et al., 1984; Rigby et al., 1984) and an increased number of
regulatory T cells (T regs) upon stimulation with vitamin D (Barrat
et al., 2002; Jeffery et al., 2009). Indeed, both juvenile/adolescent and
adult rats directly exposed to higher than regular levels of vitamin D
in the diet increased Foxp3 expression. In concord with previously
in vitro demonstrated suppressive effect of vitamin D on Th17 cells
(Chang et al., 2010), we observed vitamin D supplementation-
conditioned downregulation of Rorc, a master regulator of this T cell-
type. Our data conﬁrmed that the effect on T cells is at least partially
mediated by vitamin D-induced inhibition of IL-2 (Bhalla et al., 1986;
Rigby et al., 1984) through a downregulation of Il2 in the supplemented
group. Together with a decrease in Ifnγ and an increase in Il4, which has
previously been reported in mice (Boonstra et al., 2001), our data
support the protective immunomodulatory effect of vitamin D, which
resulted in reduced number of IFNγ producing MOG-speciﬁc T cells,
and ameliorated autoimmune response in the juvenile/adolescent rats
subjected to vitamin D supplementation.
Vitamin D supplementation in juvenile/adolescent rats led to a
milder clinical disease reﬂected in less severe CNS inﬂammation and
demyelination, and even to a decreased CD45RA+/CD4+ cell ratio in
the periphery. Besides CD4+ T cells, B-cells and antibodies may also
contribute to MS-lesion pathogenesis (Archelos et al., 2000). Similar
to the previous observation in marmoset monkeys (Merkler et al.,
2006), MOG-induced EAE in our study reﬂected MS pattern II lesions
(Lucchinetti et al., 2000) with the lowest level of antibody/complement-
mediated tissue damage in juvenile/adolescent rats fed with vitamin D
supplemented diet.
Post-natal supplementation resulted in a less severe EAE in mice
(Fernandes de Abreu et al., 2011). The ﬁve-fold enhanced vitamin D
supplemented diet was still not sufﬁcient to reduce the clinical disease
symptoms in pre- and early post-natally treated rats. The supplemented
offspring displayed, nevertheless, a tendency towards protective
immunomodulation through a decreased number of CD45RA+ B cells,
a suppressed T cell response towards MOG, as well as a tendency to
downregulate Ifnγ. Fernandes de Abreu et al. observed that prenatal
vitamin D deprivation protected offspring mice against EAE later in
adulthood (Fernandes de Abreu et al., 2010) and even speculated
about the outcome of a prolonged gestational deprivation sustained
until weaning (Fernandes de Abreu et al., 2011). In our hands, vitamin
D deprivation sustained throughout pre- and early post-natal rat devel-
opment caused no changes in susceptibility to EAE in adulthood. This
additionally indicates the importance of the early post-natal period(lactation), which has been shown to have a high impact on the rat
development (Feron et al., 2005; Lester et al., 1982). It is likely that
such offspring could not beneﬁt from the protective effect gained during
pre-natal hypovitaminosis (Fernandes de Abreu et al., 2010), due to the
vitamin D deprivation continuously being sustained until weaning.
Nevertheless, it seems that the exposure to vitamin D during juvenile/
adolescent development successfully compensated for the early post-
natal deprivation. These observations additionally emphasize the sensi-
tivity of the juvenile/adolescent age to vitamin D treatment.
Apart from increasing the levels of Foxp3, the supplementation
made no signiﬁcant impact on any other disease aspects in adult rats.
Accordingly, onemay assume that vitaminD treatment in adult patients
undergoing MS may not have the desired therapeutic effect, despite
increased serum levels of 25(OH)D. To this end, randomized phase 2
studies performed in adultMS patients deemed the inﬂuence of vitamin
D supplementation as either ineffective (Kampman et al., 2012) or
insigniﬁcant (Burton et al., 2010). Another small placebo-controlled
trial with vitamin D as an add-on treatment to interferon-β in MS
patients revealed signiﬁcantly lower numbers of T1 enhancing lesions,
but no signiﬁcant effect on MRI parameters or clinical disease variables
(Soilu-Hanninen et al., 2012). However, despite the lack of impact on all
disease aspects, fairly high supplementation doses still exhibit a consid-
erable effect on adult MS pathologies (Burton et al., 2010; Kimball et al.,
2011).
Conclusion
Our data demonstrate that vitamin D has an age-dependent efﬁcacy
to ameliorateMS-like neuroinﬂammation. Equivalent vitaminD supple-
mentation regimen carried throughout juvenile/adolescent develop-
mental stage successfully ameliorated EAE, while it was insufﬁcient to
alter the disease severity in adult rats, despite comparably increasing
the levels of 25(OH)D in serum. Moreover, the same supplementation
was not sufﬁcient to directly affect the clinical disease course in rats
treated during pre- and early post-natal development. Nevertheless, it
induced a certain degree of immunomodulation, similar to that
observed in the juvenile/adolescent rats. These results suggest that in
adulthood and for prenatal prevention purposes probably much higher
doses of supplementationwould be required for achieving theprotective
effect observed in juvenile/adolescent rats. Thus vitamin D supplemen-
tation is most efﬁcient in ameliorating neuroinﬂammation when
administered at juvenile/adolescent age.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.expneurol.2013.08.002.
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